Deltex Medical Group plc (DTXMF)

Deltex Medical Group plc, with its global presence encompassing the United Kingdom, the United States, Spain, and Canada, is dedicated to the development, marketing, and distribution of its TrueVue brand of esophageal Doppler hemodynamic monitoring systems. The company's innovative product lineup features: Esophageal Doppler Probes: These probes are engineered to accurately gauge a patient's central vascular blood flow and fluid status by continuously measuring real-time blood velocities within the descending aorta. Loops plots: This technology provides dynamic visualization of aortic blood flow velocity and aortic blood pressure, tracked meticulously with every single heartbeat. High Definition Impedance Cardiography: A non-invasive solution for monitoring cardiac function and fluid balance in conscious patients. PressureWave: An advanced algorithm that performs pulse pressure waveform analysis, particularly valuable during periods of patient instability or when the esophageal Doppler mode (ODM) is not available. Beyond monitoring devices, Deltex Medical also offers the Deltex Medical Esophageal Doppler Simulator. This tool allows clinicians to hone their skills in probe insertion, precise focusing, and waveform interpretation in a controlled, non-patient environment. These systems are critical in a variety of clinical applications, including intensive care for conditions like COVID-19 and sepsis; extensive surgical procedures such as major abdominal, laparoscopic, and spinal operations; cardiac, trauma, and organ transplant interventions; and the crucial post-operative monitoring for acute kidney injury. Founded in 2000, Deltex Medical Group plc is headquartered in Chichester, United Kingdom.

No mergers or acquisitions recorded for this company.